Search results
Results from the WOW.Com Content Network
On Oct. 10, Boston Scientific sent an urgent medical device advisory to all affected customers with recommendations. FDA classifies recall of Boston Scientific catheters as 'most serious' Skip to ...
An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding ...
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, [2] is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular ...
Shares of the medical device maker rose 1.5% in afternoon trading. The approval makes the device, branded Agent, the first drug-coated balloon catheter in the U.S. to treat coronary in-stent ...
The next day, Boston Scientific increased their bid to $25 billion, followed the next day by Johnson & Johnson increasing their bid to $24.2 billion. It was not until January 17 that Boston Scientific produced a new offer of $27.2 billion ($80 per share), with the help of Abbott Laboratories. Abbott agreed to purchase $1.4 billion of Boston ...
A drug-eluting stent (DES) is a small mesh tube that is placed in the arteries to keep them open in the treatment of vascular disease.The stent slowly releases a drug to block cell proliferation (a biological process of cell growth and division), thus preventing the arterial narrowing that can occur after stent implantation.
It utilizes the Multi-Link Vision cobalt chromium stent platform and Novartis' everolimus. The product is widely available globally including the US, the European Union, and Asia-Pacific (APAC) countries. Boston Scientific also market EESes, recent offerings being Promus Elite and Synergy. [citation needed]
Medical-device maker Boston Scientific yesterday released data from a clinical trial showing that its Promus Element drug-eluting stent showed advantages over Abbott's Xience V drug-eluting stent ...